Anxiety and depressive symptoms among patients infected with human immunodeficiency virus in South Korea

Kee, Mee Kyung; Lee, Sae Young; Kim, Na Young; Lee, Joo Shil; Kim, June Myung; Choi, Jun Yong; Ku, Nam Su; Kang, Moon Won; Woo, Jun Hee; Kim, Shin‐Woo; Song, Joon Young; Baek, Ji Hyeon; Choi, Bo Youl; Kim, Sung Soon

doi:10.1080/09540121.2015.1035861

Cited by 29 publications

(20 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…76 More recent studies have revealed that anxiety and depressive symptoms occur signi ficantly more frequently in PLWHA compared to the general population. 54 The etiological factors to both anxiety and HIV include alcohol and substance abuse, males having sex with males, or males having a bisexual relationship. 77 Increased anxiety symptoms in PLWHA were associated with being a former smoker, HIV infection detected within the past year, persistent symptoms presenting for .7 days in the past 6 months, 54 pain, concurrent substance use disorder, minimal family support, and the spouse having AIDS.…”

Section: Depression and Hiv Infectionmentioning

confidence: 99%

“…54 The etiological factors to both anxiety and HIV include alcohol and substance abuse, males having sex with males, or males having a bisexual relationship. 77 Increased anxiety symptoms in PLWHA were associated with being a former smoker, HIV infection detected within the past year, persistent symptoms presenting for .7 days in the past 6 months, 54 pain, concurrent substance use disorder, minimal family support, and the spouse having AIDS. 78 In a study based in India, anxiety disorders were detected in 36% PLWHA, the majority of whom had GAD.…”

Section: Depression and Hiv Infectionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence, impact, and management of depression and anxiety in patients with HIV: a review

Bakhla¹,

Saini²

2016

NBHIV

View full text Add to dashboard Cite

The prevalence of depression and anxiety in people living with HIV/AIDS (PLWHA) ranges from 7.2% to 71.9% and 4.5% to 82.3%, respectively. This wide variation is attributed to differences in sample size and characteristics, and methodology for assessment of anxiety and depression. Moreover, anxiety and depression increase the morbidity of HIV by poor adherence to treatment and various other significant mechanisms. Early identification and effective management of these disorders is associated with improved antiretroviral adherence and improved quality of life in PLWHA. Different treatment modalities, including pharmacological and nonpharmacological therapies, are used for the management of anxiety and depression in PLWHA. Benzodiazepines are indicated for short periods of time. Clonazepam and lorazepam are safe in terms of drug-drug interactions and may be preferred. Selective serotonin reuptake inhibitors are safer than tricyclic antidepressants. Though the different selective serotonin reuptake inhibitors are supposed to be equally effective, to avoid interactions with antiretrovirals, the better options are sertraline, citalopram, and escitalopram. Various nonpharmacological therapies, including cognitive behavior therapy, interpersonal therapy, supportive psychotherapy, cognitive-behavioral-oriented group psychotherapy, experiential group psychotherapy, cognitive-behavioral stress management, stress management interventions, cognitive remediation therapy, mindfulness-based therapy, and aerobic and resistance exercise have been reported to be useful in treating depression among PLWHA. However, definitive evidence to decide which nonpharmacological intervention is most beneficial for the management of anxiety and depression in PLWHA is still required.

show abstract

Section: Depression and Hiv Infectionmentioning

confidence: 99%

Section: Depression and Hiv Infectionmentioning

confidence: 99%

Prevalence, impact, and management of depression and anxiety in patients with HIV: a review

Bakhla¹,

Saini²

2016

NBHIV

View full text Add to dashboard Cite

show abstract

“…In chronic HIV infection, reported rates of clinically relevant depression range from 7% to 42%, with anxiety ranging from 13% to 53% [5, 6, 7, 8, 9, 10, 11]. In a study of recently infected individuals, some of whom had been infected for only a few weeks (i.e., acute HIV infection) over 20% reported suicidal ideation in the preceding month [12].…”

Section: Introductionmentioning

confidence: 99%

Depression and Anxiety are Common in Acute HIV Infection and Associate with Plasma Immune Activation

et al. 2017

View full text Add to dashboard Cite

This observational study of 123 Thai participants sought to determine the rate and severity of affective symptoms during acute HIV infection (AHI) and possible associations to disease mechanisms. At diagnosis, just prior to starting combination antiretroviral therapy (cART), AHI participants completed assessments of depression and anxiety symptoms that were repeated at 4, 12, and 24 weeks. Blood markers of HIV infection and immune activation were measured at study entry, with optional cerebrospinal fluid (CSF) measures. A high frequency of participants reported symptoms that exceeded published thresholds supportive of depression (55.0%) and anxiety (65.8%) at diagnosis, with significant reductions after starting cART. Meeting a threshold for clinically relevant depressive symptoms at study entry was associated with higher baseline plasma HIV RNA (5.98 vs. 5.50, t=2.46, p=0.015), lower CD4 counts (328 vs. 436 cells/mm3, t=3.46, p=0.001), and higher plasma neopterin, a marker of macrophage activation (2694 vs. 1730 pg/mL, Mann-Whitney U = 152.5, p=0.011). Controlling for plasma HIV RNA and CD4 count, higher baseline plasma neopterin correlated with worse initial depression and anxiety scores. Depression and anxiety symptoms are frequent in acute HIV infection, associate with plasma immune activation, and can improve concurrent with cART.

show abstract

“…Initial diagnosis with HIV is associated with significant stress, as is the prospect of disclosure of diagnosis and having to live with HIV (Hult et al, 2012; Olley et al, 2005). While the general diagnosis and prevalence of anxiety and depression vary across cultures (Lewis-Fernandez et al, 2010), these symptoms have been widely reported in HIV-positive patient cohorts across the globe (Kee et al, 2015; Mutumba et al, 2015; Tesfaye and Bune, 2014). This cross-cultural prevalence raises the possibility that in addition to psychosocial stressors, a component of HIV infection may trigger anxiety symptoms.…”

Section: Introductionmentioning

confidence: 99%

Expression of gp120 in mice evokes anxiety behavior: Co-occurrence with increased dendritic spines and brain-derived neurotrophic factor in the amygdala

Bachis

Forcelli

Masliah

et al. 2016

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

Human immunodeficiency virus type 1 (HIV) infection of the brain produces cognitive and motor disorders. In addition, HIV positive individuals exhibit behavioral alterations, such as apathy, and a decrease in spontaneity or emotional responses, typically seen in anxiety disorders. Anxiety can lead to psychological stress, which has been shown to influence HIV disease progression. These considerations underscore the importance of determining if anxiety in HIV is purely psychosocial, or if by contrast, there are the molecular cascades associated directly with HIV infection that may mediate anxiety. The present study had two goals: 1) to determine if chronic exposure to viral proteins would induce anxiety-like behavior in an animal model and 2) to determine if this exposure results in anatomical abnormalities that could explain increased anxiety. We have used gp120 transgenic mice, which display behavior and molecular deficiencies similar to HIV positive subjects with cognitive and motor impairments. In comparison to wild type mice, 6 months old gp120 transgenic mice demonstrated an anxiety like behavior measured by open field, light/dark transition task, and prepulse inhibition tests. Moreover, gp120 transgenic mice have an increased number of spines in the amygdala, as well as higher levels of brain-derived neurotrophic factor and tissue plasminogen activator when compared to age-matched wild type. Our data support the hypothesis that HIV, through gp120, may cause structural changes in the amygdala that lead to maladaptive responses to anxiety.

show abstract

Anxiety and depressive symptoms among patients infected with human immunodeficiency virus in South Korea

Cited by 29 publications

References 27 publications

Prevalence, impact, and management of depression and anxiety in patients with HIV: a review

Prevalence, impact, and management of depression and anxiety in patients with HIV: a review

Depression and Anxiety are Common in Acute HIV Infection and Associate with Plasma Immune Activation

Expression of gp120 in mice evokes anxiety behavior: Co-occurrence with increased dendritic spines and brain-derived neurotrophic factor in the amygdala

Contact Info

Product

Resources

About